Source: Sienna Biopharmaceuticals Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA), a clinical-stage medical dermatology and aesthetics company, today announced results from a Phase 1b maximal use (MUse) pharmacokinetic (PK) and safety study of SNA-120 (pegcantratinib), a Phase 2b drug candidate being evaluated as a topical, nonsteroidal therapy to treat itch (pruritus) associated with psoriasis.…...

Source: FierceBiotech A new CSO isn't all Dermavant got from GlaxoSmithKline: The Roivant unit has picked up the rights to the British drugmaker's dermatology drug tapinarof in a deal worth up to £250 million ($330 million). The asset is poised to enter phase 3 in psoriasis and atopic dermatitis and is also…...

Source: Cassiopea Lainate, Italy – 10 July 2018 - Cassiopea SpA (SIX: SKIN), a clinical-stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products, today announced that top line results from two pivotal phase 3 clinical trials for its topical anti-androgen Winlevi® cream 1% (Clascoterone) demonstrated…...

Source: Reuters Amazon.com Inc said on Thursday it would buy small online pharmacy PillPack, a move that will put the world’s biggest online retailer in direct competition with drugstore chains, drug distributors and pharmacy benefit managers. The deal’s potential to disrupt major players across the drug supply chain nationwide prompted…...

Source: FierceBiotech Verrica Pharmaceuticals has filed to raise $86 million from public investors. The planned IPO will give Verrica the money it needs to take a treatment for viral skin infection molluscum through phase 3 and onto the market. West Chester, Pennsylvania-based Verrica’s lead candidate is VP-102, a drug-device combination.…...

Source: Japan’s Takeda Pharmaceutical is about to become a major international player on the biopharma scene, with its purchase of larger Irish rival Shire (SHPG, +1.41%). It’s one of the biggest pharma deals in history, and the largest-ever international takeover by any Japanese company, at a value of $62 billion.…...

Source: Business Wire MALVERN, Pa.--(BUSINESS WIRE)--Encore Dermatology Inc. announces today the availability of a new topical product, IMPOYZ Cream, indicated for the treatment of moderate to severe plaque psoriasis in patients 18 years of age or older. IMPOYZ Cream is the only FDA-approved high-potency topical corticosteroid with 0.025% clobetasol propionate.…...

Source: PR Newswire SAN FRANCISCO, April 30, 2018 /PRNewswire/ -- Datavant, the leader in helping healthcare organizations safely link their data to improve medical research and patient care, today announced that it has acquired Universal Patient Key (UPK), the leading provider of HIPAA-compliant de-identification services for healthcare data. UPK has…...

Source: "Sun Pharma" and includes its subsidiaries and/or associate companies) announced that the U.S. Food and Drug Administration (FDA) has approved ILUMYA™ (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ILUMYA selectively binds to the p19 subunit of IL-23 and…...

Source: Drives greater affordability and connectivity with customers and their health care providers, while making health care simpler Creates an expanded portfolio of health services with greater choice, alignment and value across a proven services platform Expands distribution of health services for employers, health plans and government agencies Delivers first…...